Challenge: Assist in developing a vaccine for HIV
Approach: Actively partner with industry experts and develop an internal point of view on HIV vaccine development
Outcomes: KBI has been on the forefront of HIV vaccine development for many years. Abhinav Shukla, our SVP of Process Development and Manufacturing has been a thought leader in this subject for many years. He has given multiple presentations on the subject and is regarded as an expert in the field.
In 2015 KBI was contracted to produce the CH505 vaccine for the Duke CHAVI-ID team according to good manufacturing practices (GMP) and the clinical trials were designed by the HIV Vaccine Trials Network. This is the first such vaccine where immunization regimens are based on the envelope proteins that induce BnAbs in vivo.
The Duke CHAVI-ID has received support from the Division of AIDS, the NIAID, and the NIH for the GMP production of Envs for this trial.
We have also worked with Thomas N. Denny, MSc, M.Phil, and Professor of Medicine at Duke University on a platform process that works for producing/purifying an array of these complex glycoproteins for HIV .
Here are several presentations we have given on the subject:
- HIV Vaccines Process Development & Manufacturing: Pitfalls & Possibilities
- A Vaccine Approach Against HIV-1, Manufacturing Env Proteins: From Bench to Bedside
- Development and Implementation of a Platform Process for HIV Vaccine
To learn more about the CH505 Vaccine visit: https://chavi-id-duke.org/research/vaccine-design
